Hormonal
Tirzepatide (10 mg and 15 mg) provides statistically superior weight reduction and waist circumference reduction compared to semaglutide (2.4 mg) and liraglutide (3 mg) in patients with obesity or overweight without type 2 diabetes.
For patients with obesity or overweight without type 2 diabetes, Tirzepatide (10mg and 15mg doses) administered once weekly, alongside lifestyle changes, achieves significantly greater weight loss and waist circumference reduction than Semaglutide (2.4mg) or Liraglutide (3mg). The safety profile is generally comparable across all three treatments.
Efficacy estimand results showed all tirzepatide doses were associated with statistically greater improvements in weight reduction outcomes versus liraglutide, and for tirzepatide 10 and 15 mg versus semaglutide: including percentage weight reduction (− 12.86% for tirzepatide 10 mg and − 13.95% for tirzepatide 15 mg versus liraglutide; − 4.85% and − 6.26% versus semaglutide) and waist circumference (− 11.79 cm and − 12.30 cm versus liraglutide; − 4.81 cm and − 5.32 cm versus semaglutide).
Why this rating
Bayesian Network Meta-Analysis of Randomized Controlled Trials, though limited to 6 studies.
Source
Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials
Andreea Ciudin et al. · Advances in Therapy · 2026
DOI 10.1007/s12325-026-03523-5
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →